These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 6418881)

  • 1. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
    Schumacher WA; Lucchesi BR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
    Dale J; Thaulow E; Myhre E; Parry J
    Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T
    Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Buja LM; Tilton GD; Willerson JT
    Circulation; 1984 Jun; 69(6):1161-70. PubMed ID: 6546902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboxane-mediated activation of platelets and enhancement of platelet uptake onto collagen-coated glass or deendothelialized rabbit aorta. Comparative effects of a thromboxane antagonist (EPO45) and a thromboxane synthetase inhibitor (dazoxiben).
    Menys VC; Davies JA
    Lab Invest; 1984 Feb; 50(2):184-9. PubMed ID: 6546403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the thromboxane synthetase inhibitor Dazoxiben (UK 37-248) on the metabolism of antipyrine in patients with enhanced platelet aggregation.
    Staiger C; Walter E; Wang NS; Schuhmacher E; de Vries J; Weber E
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):250-3. PubMed ID: 6540249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro.
    O'Keefe EH; Liu EC; Greenberg R; Ogletree ML
    Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
    FitzGerald GA; Brash AR; Oates JA; Pedersen AK
    J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the selective thromboxane synthetase inhibitor, dazoxiben, on cyclic flow variations in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Tilton GD; Buja LM; Willerson JT
    Trans Assoc Am Physicians; 1983; 96():103-12. PubMed ID: 6687298
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine.
    Gross GJ; Moore J
    Pharmacology; 2004 Jul; 71(3):135-42. PubMed ID: 15161995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
    Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
    Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ
    Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion.
    Menys VC; Davies JA
    Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
    Sills T; Heptinstall S
    Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease.
    Hutton I; Tweddel AC; Rankin AC; Walker ID; Davidson JF
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):79S-82S. PubMed ID: 6681709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors.
    Korbut R; Dembińska-Kieć A; Swies J; Zmuda A; Gryglewski RJ
    Thromb Haemost; 1987 Oct; 58(3):827-30. PubMed ID: 3324381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.